<DOC>
	<DOCNO>NCT02064439</DOCNO>
	<brief_summary>This multicenter , randomize , double-blind , event-driven , superiority study efficacy . Patients confirm symptomatic DVT ( Deep Vein Thrombosis ) PE ( Pulmonary embolism ) complete 6 12 month treatment anticoagulation eligible trial</brief_summary>
	<brief_title>Reduced-dosed Rivaroxaban Long-term Prevention Recurrent Symptomatic VTE ( Venous Thromboembolism )</brief_title>
	<detailed_description />
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Pulmonary Embolism</mesh_term>
	<mesh_term>Venous Thrombosis</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Patients confirm symptomatic PE and/or DVT treat 6 12 month interrupt anticoagulation longer 1 week Legal low age limitation ( country specific ) Indication therapeuticdosed anticoagulant Indication antiplatelet therapy conventional nonsteroid antiinflammatory drug ( NSAID ) Hepatic disease associate coagulopathy lead clinically relevant bleeding risk Calculated creatinine clearance &lt; 30 mL/min</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>deep vein thrombosis</keyword>
	<keyword>pulmonary embolism</keyword>
	<keyword>long-term prevention recurrent symptomatic VTE</keyword>
</DOC>